Clinical Trial Update: A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC [Phase 2]

View source ↗

Summary

Phase II trial comparing SHR-1210 versus placebo as consolidation after radical chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. The cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• SHR-1210 (camrelizumab)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN